Redx Pharma has raised $36.0M in a Series A round backed by Abingworth, a bet on the clinical-stage biotech’s pipeline of small-molecule drugs targeting cancer and fibrotic diseases. The Cheshire-based company, which operates out of the UK’s largest single-site life science campus at Alderley Park, is pushing forward with three lead candidates: zelasudil, a ROCK2 inhibitor in Phase 2 for idiopathic pulmonary fibrosis; RXC008, a GI-targeted pan-ROCK inhibitor that entered Phase 1 for fibrostenotic Crohn’s disease; and zamaporvint, a Porcupine inhibitor in Phase 2 for oncology. The fresh capital arrives as Redx leans on its medicinal chemistry and translational science strengths to differentiate itself in crowded therapeutic areas, though the company has not detailed how the funds will be deployed.
Redx Pharma Raises $36.0M Series A
Get the full Redx Pharma company profile
Access contacts, investors, buying signals & more
From the source
bioSeedin · Aug 29, 2026💰 𝐖𝐞𝐞𝐤𝐥𝐲 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 𝐑𝐨𝐮𝐧𝐝𝐮𝐩A busy week across the biopharma capital markets, led by multibillion-dollar convertible offerings and continued investor support for late-stage clinical assets.𝟏. Moderna — $𝟐.𝟔𝐁 𝐂𝐨𝐧𝐯𝐞𝐫𝐭𝐢𝐛𝐥𝐞 𝐍𝐨𝐭𝐞𝐬Moderna priced an upsized $2.
6 billion offering of 0% convertible senior notes due 2032, with an additional $400 million purchase option. The offering is expected to close on September 1.𝟐.Samsung Biologics — 𝐊𝐑𝐖𝟑𝐓 𝐑𝐢𝐠𝐡𝐭𝐬 𝐎𝐟𝐟𝐞𝐫𝐢𝐧𝐠Samsung Biologics proposed a KRW3 trillion rights offering. Approximately KRW2.71 trillion is intended to fund its planned acquisition of PolyPeptide Group, with the balance suppo
Other United Kingdom companies recently funded
View all
Fraiya Ultrasound
At Fraiya Ltd, our mission is to revolutionize the field of ultrasound through cutting-edge artificial intelligence technology. Fraiya aims to elevate the standard of prenatal care by advancing the accuracy, consistency, and efficiency of ultrasound, supporting more confident clinical decisions and a more reassuring experience for every mother and baby. The Fraiya Platform is designed to work together across the prenatal pathway, starting with the anomaly scan, to improve consistency, reduce workload and raise the standard of care.
$4.8M Pre-seed
today
Maiden Cricket
Maiden Cricket exists for one reason: women and girls deserve cricket kit designed for them, not shrunk-down, pinked-up versions of men’s gear. Founded by sisters Honor and Cat Black, Maiden is the UK’s purpose-built cricket brand for women and girls, spanning playing kit, teamwear and protective equipment. Everything we make is built on three pillars: Confidence Starts With Fit, kit cut for female bodies, so players can focus on their game, not their gear. Protection With Purpose, equipment designed around how women and girls actually play. Representation & Community, because you can’t be what you can’t see. We supply clubs, schools, universities and counties with Teamwear, and we’re proud to partner with county boards and grassroots programmes across the UK. Our 300+ strong ambassador community, from Rising Stars to professional players, is at the heart of everything we do. Whether you’re kitting out a first XI, launching a Women’s and Girls’ section, or looking for a partner in growing the women’s game, we’d love to talk. Teamwear enquiries: b.black@maiden-cricket.co.uk Buy Online: www.maiden-cricket.co.uk
Biggest recent Biotechnology rounds
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 |  NeuroEM Therapeutics United States | Unknown |
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Payload United States | Series a | $9.0M | today |
| 2 |  Retro | Series a | $21.0M | today |
